8-K
filed January 5, 2024, 6:59 PM ET
ticker CERO
CIK 0001870404
other material
confidence high
sentiment neutral
materiality 0.65
Phoenix Biotech SPAC extends merger deadline to Apr 8, 2024; 11,625 shares redeemed
CERO THERAPEUTICS HOLDINGS, INC.
- Stockholders approved Charter and Trust amendments to allow up to three monthly extensions from Jan 8 to Apr 8, 2024.
- Sponsor deposited $22,599.96 into trust account for the first extension period.
- Redemption of 11,625 Class A shares at $11.02 per share reduced trust balance to ~$8.3M.
- Post-redemption, 6,234,582 Class A shares outstanding; 753,332 are public shares with redemption rights.
- Certificate of Correction filed Jan 4, 2024 to fix scrivener's errors in the Charter Amendment.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC.: Amended charter to allow board to extend business combination deadline up to three additional months, and to provide redemption rights without tender offer rules (effective 2024-01-03).
- Change
- charter amendment
- Effective
- 2024-01-03
Exact text from the filing
On January 3, 2024, the Company’s stockholders approved an amendment (the “ Charter Amendment ”) to the Company’s amended and restated certificate of incorporation, as amended by the First Amendment dated December 20, 2022 and the Second Amendment dated July 7, 2023 (the “ Charter ”), to provide its board of directors the ability to extend the date by which the Company has to consummate a business combination up to three times for one month each time, for a maximum of three additional months.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.7
CERO THERAPEUTICS HOLDINGS, INC. amended Trust Agreement Amendment with Continental Stock Transfer and Trust Company (effective 2024-01-03).
- Action
- amendment
- Counterparty
- Continental Stock Transfer and Trust Company
- Effective
- 2024-01-03
Exact text from the filing
Trust Agreement Amendment At the Special Meeting, the Company’s stockholders approved a proposal to amend (the “ Trust Agreement Amendment ”) the Investment Management
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Charter Amendment Proposal - to amend the Charter to extend the business combination period at the 2024-01-03 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2024-01-03
Exact text from the filing
Proposal 1 - The Charter Amendment Proposal - a proposal to amend the Charter to (a) provide its board of directors the ability to extend the date by which the Company has to consummate a business combination up to three times for one month each time from January 8, 2024 to February 8, 2024, March 8, 2024 or April 8, 2024 and (b) allow for the Company to provide redemption rights to the Company’s public stockholders in accordance with the requirements of the charter without complying with the tender offer rules. For Against Abstain 5,538,823 11,070 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CERO THERAPEUTICS HOLDINGS, INC. shareholders approved Trust Amendment Proposal - to amend the Trust Agreement to extend the business combination period at the 2024-01-03 meeting.
- Proposal
- merger approval
- Outcome
- passed
- Meeting
- 2024-01-03
Exact text from the filing
Proposal 2 - The Trust Amendment Proposal - a proposal to amend the Trust Agreement to extend the business combination period up to three times for one month each time from January 8, 2024 to February 8, 2024, March 8, 2024 or April 8, 2024. For Against Abstain 5,538,811 11,082 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.